Literature DB >> 10711278

A further cohort study of workers employed at a factory manufacturing chemicals for the rubber industry, with special reference to the chemicals 2-mercaptobenzothiazole (MBT), aniline, phenyl-beta-naphthylamine and o-toluidine.

T Sorahan1, L Hamilton, J R Jackson.   

Abstract

OBJECTIVES: To investigate mortality and cancer morbidity in workers from a factory manufacturing chemicals for the rubber industry.
METHODS: The mortality (1955-96) and cancer morbidity experience (1971-92) of a cohort of 2160 male production workers from a chemical factory in north Wales were investigated. All subjects had at least 6 months employment at the factory and some employment in the period 1955-84. Detailed job histories were abstracted from company computerised records and estimates of individual cumulative exposure to 2-mercaptobenzothiazole (MBT) and its derivatives were obtained, with a job exposure matrix derived by a former factory hygienist. Durations of employment in the aniline, phenyl-beta-naphthylamine (PBN) and o-toluidine departments were also calculated. Two analytical approaches were used, indirect standardisation and Poisson regression.
RESULTS: Based on serial rates for the general population of England and Wales, observed mortality for the total cohort was close to expectation for all causes (observed (obs) deaths 1131, expected (exp) deaths 1114.5, standardised mortality ratio (SMR) 101), and for all cancers (obs 305, exp 300.2, SMR 102). There was a significant (p < 0.05) excess mortality from cancer of the bladder in the 605 study subjects potentially exposed to one or more of the four chemicals being investigated (obs 9, exp 3.25, SMR 277, 95% confidence interval (95% CI) 127 to 526). This excess was dependent primarily on deaths occurring > 20 years after first exposure in those who started employment before 1955 (obs 7, exp 1.25, SMR 560, 95% CI 225 to 1154, p < 0.001). There were 30 subjects in the total study cohort who, on the basis of death certificates or cancer registration particulars, had had malignant bladder cancer. In separate analyses of the four exposure history variables (after adjustment for age), Poisson regression showed significant positive trends for risk of notification of bladder cancer increasing with cumulative duration of employment in the PBN (p < 0.001) and o-toluidine departments (p < 0.01); similar findings were not obtained for cumulative exposure to MBT or for duration of employment in the aniline department. In a simultaneous analysis of all four chemical exposure variables, a significant positive trend remained for duration of employment with exposure to PBN (p < 0.05). Further analyses of all cases of bladder cancer (malignant and benign diagnoses) used employment histories lagged by 15 years; similar findings were obtained.
CONCLUSIONS: It seems likely that some members of this cohort have had occupational bladder cancer. Confident interpretation is difficult because of small numbers in the exposed subcohorts, relatively crude measures of exposure assessment for the four chemicals under study, and presence of unconsidered potential chemical confounders. The simplest interpretation of the findings about bladder cancer may be that PBN (or a chemical reagent or chemical intermediate associated with its production at this factory in the 1930s and 1940s) is a bladder carcinogen. Priority should be given, however, to obtaining information on the cancer experience of other working populations exposed to PBN or to o-toluidine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10711278      PMCID: PMC1739914          DOI: 10.1136/oem.57.2.106

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  12 in total

1.  An alternative hypothesis for bladder cancer among workers exposed to ortho-toluidine and aniline.

Authors:  J F Acquavella; J D Wilson; P Conner; R Bannister
Journal:  J Natl Cancer Inst       Date:  1991-11-20       Impact factor: 13.506

2.  Cohort study analysis with a FORTRAN computer program.

Authors:  M Coleman; A Douglas; C Hermon; J Peto
Journal:  Int J Epidemiol       Date:  1986-03       Impact factor: 7.196

3.  Bladder cancer due to exposure to para-aminobiphenyl: a 17-year followup.

Authors:  W F Melick; J J Naryka; R E Kelly
Journal:  J Urol       Date:  1971-08       Impact factor: 7.450

4.  The chronic effects of magenta, paramagenta and phenyl-beta-naphthylamine in rats after intragastric administration.

Authors:  M B Ketkar; U Mohr
Journal:  Cancer Lett       Date:  1982 Jul-Aug       Impact factor: 8.679

5.  A comparative study of the chronic effects of magenta, paramagenta, and phenyl-beta-naphthylamine in Syrian golden hamsters.

Authors:  U Green; J Holste; A R Spikermann
Journal:  J Cancer Res Clin Oncol       Date:  1979-09       Impact factor: 4.553

6.  Excess number of bladder cancers in workers exposed to ortho-toluidine and aniline.

Authors:  E Ward; A Carpenter; S Markowitz; D Roberts; W Halperin
Journal:  J Natl Cancer Inst       Date:  1991-04-03       Impact factor: 13.506

7.  Mortality experience of employees exposed to 2-mercaptobenzothiazole at a chemical plant in Nitro, West Virginia.

Authors:  M E Strauss; E D Barrick; R M Bannister
Journal:  Br J Ind Med       Date:  1993-10

8.  Hepatic microsomal metabolism and macromolecular binding of the antioxidant, N-phenyl-2-naphthylamine.

Authors:  M M Anderson; R K Mitchum; F A Beland
Journal:  Xenobiotica       Date:  1982-01       Impact factor: 1.908

9.  Biological conversion of N-phenyl-2-naphthylamine to 2-naphthylamine in the Sprague-Dawley rat.

Authors:  S Laham; M Potvin
Journal:  Drug Chem Toxicol       Date:  1983       Impact factor: 3.356

Review 10.  Reevaluating the carcinogenicity of ortho-toluidine: a new conclusion and its implications.

Authors:  C Sellers; S Markowitz
Journal:  Regul Toxicol Pharmacol       Date:  1992-12       Impact factor: 3.271

View more
  7 in total

Review 1.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

Review 2.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

3.  [The causes of urinary bladder cancer and possibilities of prevention].

Authors:  K Golka; A W Rettenmeier; P J Goebell
Journal:  Urologe A       Date:  2006-03       Impact factor: 0.639

Review 4.  Occupational exposure and urological cancer.

Authors:  Klaus Golka; Andreas Wiese; Giorgio Assennato; Hermann M Bolt
Journal:  World J Urol       Date:  2003-11-26       Impact factor: 4.226

Review 5.  Medical follow-up for workers exposed to bladder carcinogens: the French evidence-based and pragmatic statement.

Authors:  Bénédicte Clin; Jean-Claude Pairon
Journal:  BMC Public Health       Date:  2014-11-06       Impact factor: 3.295

Review 6.  Non‑infective occupational risk factors for hepatocellular carcinoma: A review (Review).

Authors:  Caterina Ledda; Carla Loreto; Christian Zammit; Andrea Marconi; Lucrezia Fago; Serena Matera; Valentina Costanzo; Giovanni Fuccio Sanzà; Stefano Palmucci; Margherita Ferrante; Chiara Costa; Concettina Fenga; Antonio Biondi; Cristoforo Pomara; Venerando Rapisarda
Journal:  Mol Med Rep       Date:  2016-12-14       Impact factor: 2.952

7.  Quantification of N-phenyl-2-naphthylamine by gas chromatography and isotope-dilution mass spectrometry and its percutaneous absorption ex vivo under workplace conditions.

Authors:  Eike Maximilian Marek; Stephan Koslitz; Tobias Weiss; Manigé Fartasch; Gerhard Schlüter; Heiko Udo Käfferlein; Thomas Brüning
Journal:  Arch Toxicol       Date:  2017-09-12       Impact factor: 5.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.